Pamidronic acid

Generic Name: Pamidronic acid

Brand Names: Pamisol

Drug Type: Small Molecule

Chemical Formula: C_₃H_₁₁NO_₇P_₂

CAS Number: 40391-99-9

Unique Ingredient Identifier: OYY3447OMC

Background: Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.

Pamidronic acid was granted FDA approval on 31 October 1991.

Indication: Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.

Associated Conditions: Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases

Clinical Trials

Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention

Phase 4

Completed

Conditions: Osteopenia
Other Complications of Lung Transplant
Complications of Heart-lung Transplant

First Posted Date: 2005-09-14

Last Posted Date: 2013-12-05

Lead Sponsor: Bayside Health

Target Recruit Count: 56

Registration Number: NCT00164008

Bisphosphonate Therapy for Osteogenesis Imperfecta

Phase 4

Completed

Conditions: Osteogenesis Imperfecta
Osteoporosis
Paget Disease of Bone

Interventions: Drug: Pamidronate
Drug: Alendronate

First Posted Date: 2005-09-12

Last Posted Date: 2017-06-14

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 18

Registration Number: NCT00159419

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Phase 4

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

Interventions: Drug: Pamidronate

First Posted Date: 2005-08-09

Last Posted Date: 2023-03-28

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 152

Registration Number: NCT00128297

Locations: 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: pamidronate disodium
Drug: arsenic trioxide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2005-07-28

Last Posted Date: 2013-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00124605

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Osteopenia and Renal Osteodystrophy: Evaluation and Management

Phase 4

Completed

Conditions: Osteopenia
Renal Osteodystrophy

First Posted Date: 2005-04-15

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00108394

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain

Phase 1

Conditions: Low Back Pain

Interventions: Drug: pamidronate

First Posted Date: 2005-01-14

Last Posted Date: 2010-01-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 44

Registration Number: NCT00101790

Locations: 🇺🇸
The Mount Sinai Medical Center, New York, New York, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004906

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2004-05-25

Last Posted Date: 2010-07-05

Lead Sponsor: University of Arkansas

Target Recruit Count: 20

Registration Number: NCT00083408

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pamidronate
Drug: Thalidomide
Drug: Zometa

First Posted Date: 2004-05-24

Last Posted Date: 2015-06-24

Lead Sponsor: University of Arkansas

Target Recruit Count: 83

Registration Number: NCT00083382

Locations: 🇺🇸
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2014-04-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00033332

Locations: 🇺🇸
Veterans Affairs Medical Center - Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
CCOP - Scott and White Hospital, Temple, Texas, United States
🇺🇸
Veterans Affairs Medical Center - Madison, Madison, Wisconsin, United States

and more 75 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy